Krystal Biotech, Inc.
KRYS
Classificação em ações
#2151
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Preço da ação
$320.50
Última sincronização: 2026-10-19
Valor de mercado
$9.49B
Variação (1 dia)
1.24%
Variação (1 ano)
63.55%
País
US
Negociar Krystal Biotech, Inc. (KRYS)
Categoria
Healthcare
Rácio P/S de Krystal Biotech, Inc. (KRYS)
Rácio P/S em October 2026 TTM: 22.22
De acordo com os relatórios financeiros mais recentes e o preço das ações da Krystal Biotech, Inc., o rácio P/S atual (TTM) é 22.22. No final de 2023, o rácio P/S era 66.45.
Histórico do rácio P/S da Krystal Biotech, Inc. de 2016 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 22.22 | 44.11% |
| 2024 | 15.42 | -76.80% |
| 2023 | 66.45 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | 226.68 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | -54.90% |
US
|
|
| 40.55 | 82.49% |
US
|
|
| 3.96 | -82.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -54.34% |
NL
|
